FDA Biopharmaceutical Product Approvals and Trends: 2011


Table 1.  FDA Full Biopharmaceutical Approvals in 2011**
Product
Company
Date
Indication
VEGF Trap, rDNA (Eylea) Regeneron Pharmaceuticals Inc.11/18/2011age-related macular degeneration
Asparaginase/Erwinia (Erwinaze)* EUSA Pharma Inc.11/18/2011acute lymphoblastic leukemia
Cord blood stem cells (Hemacord) New York Blood Center, Inc. 11/10/2011 hematopoietic stem cell transplantation
CD30 mAb, rDNA--monomethyl auristatin E (Adcetris)* Seattle Genetics, Inc 8/19/2011Hodgkin's lymphoma
Scorpion antitoxin/immunoglobulin, equine (Anascorp)* Rare Disease Therapeutics Inc.8/3/2011 scorpion stings
Fibroblasts, autologous (laViv)* Fibrocell Science, Inc. 6/22/2011 nasolabial fold wrinkles (smile lines)
CTLA4-Ig, rDNA (Nulojix)* Bristol-Myers Squibb 6/15/2011 kidney transplant rejection
Albumin, human (Kedbumin)* Kedrion, S.p.A. 6/3/2011 multiple albumin supplementation indications
CTLA-4 Mab, rDNA/Medarex (Yervoy)* Bristol-Myers Squibb 3/25/2011 melanoma
Adenovirus Type 4, 7 Vaccine Live, oral (Ardovax) Teva Pharmaceuticals 3/16/2011 vaccination of U.S. military personnel only
B-cell-activating factor Mab, rDNA (Benlysta) Human Genome Sciences Inc. 3/9/2011 systemic lupus erythematosus
Factor XIII, human (Corifact)* CSL Behring 2/17/2011 Factor XIII deficiency